Astragaloside IV and Kidney Cell Injury
Author Information
Author(s): Liu Wenyuan, Liu Qianwei, Zhang Ziyuan, Hu Yaling, Fang Jingai
Primary Institution: The First Hospital, Shanxi Medical University
Hypothesis
This study aims to explore the mechanism of astragaloside IV (AS-IV) in the treatment of UII-mediated renal tubular epithelial cell injury.
Conclusion
AS-IV may improve UII-mediated renal tubular epithelial cell damage by down-regulating the cAMP/PKA signaling pathway.
Supporting Evidence
- The cAMP signaling pathway is one of the most important pathways for AS-IV to treat CKD.
- Molecular docking results showed that AS-IV can be well embedded in the active pockets of target proteins.
- AS-IV may down-regulate the cAMP/PKA signaling pathway to protect renal tubular epithelial cells.
Takeaway
This study found that a substance called astragaloside IV can help protect kidney cells from damage caused by another substance, urotensin II, by affecting certain signaling pathways in the cells.
Methodology
The study used network pharmacology and experimental validation, including molecular docking, CCK8 assay, ELISA, RT-PCR, and Western blot methods.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website